NCT03695809 is a clinical trial of G9a protein in Vulvar Cancer, G9a Protein, sponsored by Far Eastern Memorial Hospital.

Who is sponsoring NCT03695809?

NCT03695809 is sponsored by Far Eastern Memorial Hospital.

What drugs are being tested in NCT03695809?

Interventions in NCT03695809: G9a protein.

What condition does NCT03695809 study?

NCT03695809 studies Vulvar Cancer, G9a Protein.

Is NCT03695809 still recruiting?

NCT03695809 is currently status unknown. Last updated 29 March 2023.

Last reviewed 2023-03-29 · How we verify

NCT03695809

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Association of G9a Protein and Clinical Outcome of Patients With Vulvar Cancer

Status unknown Last updated 29 March 2023

What this trial tests

trial testing G9a protein in Vulvar Cancer, G9a Protein in 30 participants. Status unknown.

Timeline

20 April 2018

Primary endpoint
31 December 2024

31 December 2024

Quick facts

Lead sponsor	Far Eastern Memorial Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	30
Start date	20 April 2018
Primary completion	31 December 2024
Estimated completion	31 December 2024
Sites	1 location across Taiwan

Drugs / interventions tested

G9a protein — full drug profile →

Conditions studied

Vulvar Cancer, G9a Protein — all drugs for Vulvar Cancer, G9a Protein →

Sponsor

Far Eastern Memorial Hospital

Who can join

20 and older, female only, with Vulvar Cancer, G9a Protein. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To assess the G9a expression in vulvar cancer

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

BCL-G: 20 years of research on a non-typical protein from the BCL-2 family.
Hartman ML, Czyz M. · · 2023 · cited 12× · PMID 37031274 · DOI 10.1038/s41418-023-01158-5

Verify or expand the search:

Other Far Eastern Memorial Hospital trials

Trials by the same sponsor.

NCT07385976 — The Role of Blood Perfusion in Cervical Cancer, Cervical Intraepithelial Neoplasm and Ovarian Cancer Patients · not yet recruiting
NCT07107542 — Exploring the Relationship Between Mini-Clinical Evaluation Exercise (Mini-CEX) and Entrustable Professional Activities · not yet recruiting
NCT07114653 — The Role of POLE Mutation in High Risk Endometrial Cancer. · recruiting
NCT07105345 — Exploring Efficacy of Multi-Mode Cognitive Processing Therapy (CPT) for PTSD · NA · recruiting
NCT07110350 — Clinical Outcomes of Non-Indicated Staged Laparotomies in Abdominal Trauma · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03695809 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Far Eastern Memorial Hospital
Last refreshed: 29 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03695809.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing